Immune Checkpoint Inhibitors in Head and Neck Cancer: Current Evidence and Future Directions

Pre-registration for the in-person event is now close is now closed. We welcome you to register on-site by coming to the JW Marriott Austin, Room 402-403 (Level 4). Remember to bring your COSM badge to expedite your registration.


6:00 PM – 6:30 PM
Registration and Dinner

6:30 PM - 6:40 PM
Program Overview

6:40 PM - 7:10 PM
Rationale for Immune Checkpoint Inhibitors and Optimizing Treatments for Recurrent or Metastatic HNSCC – Barbara Ann Burtness, MD

7:10 PM - 7:40 PM
Practical Guidance for Clinical Integration of Immune Checkpoint Inhibitors
Robert L. Ferris, MD, PhD

7:40 PM – 8:10 PM
What Does the Future Hold for Immuno-Oncology in HNSCC?
Cristina P. Rodriguez, MD

8:10 PM - 8:30 PM
Panel Discussion and Audience Question and Answer Session


Date / Time
Event Details


Program Chair
Barbara Burtness, MD

Professor of Medicine 
Yale University School of Medicine
Co-Leader, Developmental Therapeutics Program
Yale Cancer Center
New Haven, Connecticut

Robert Ferris, MD

UPMC Hillman Cancer Center
Hillman Professor of Oncology
Associate Vice-Chancellor for Cancer Research

University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Cristina Rodriguez, MD

Associate Professor
Department of Medicine
University of Washington
Seattle, Washington

Goal Statement
The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating immunotherapy into the treatment of patients with head and neck cancer.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with head and neck cancer.

Learning Objectives 

  • Gain insight on the role of the immune system and immune escape in HNSCC, along with the mechanisms of action of different immune modulatory agents
  • Plan therapeutic strategies for patients with recurrent or metastatic HNSCC that has progressed on or after platinum-containing chemotherapy
  • Evaluate the latest science and clinical trial results of immune checkpoint inhibitors in adjuvant and neoadjuvant settings and alone or in combination with radiotherapy or biotherapy across all indications
  • Identify patients who would benefit from immunotherapy based on optimal assessment of predictive biomarkers
  • Manage immune-related toxicities associated with immune checkpoint inhibitors in patients with HNSCC


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Education
CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.